Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Knowledge about metabolic capacity is important in drug therapy].

Lakartidningen - 5 Feb 1992

Alván G, Dahl M L

Abstract excerpt

Genetic polymorphisms are common and are also found for drug metabolising enzymes such as acetyltransferase and two distinct cytochrome P-450 isoenzymes that catalyse the oxidative metabolism of the model drugs debrisoquine and S-mephenytoin respectively. Thus, individual metabolic activity can b...

Topics

Cytochrome P-450 Enzyme System
Debrisoquin
Humans
Mephenytoin
Pharmaceutical Preparations
Phenotype
Polymorphism, Genetic

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 1738265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-1738265-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Knowledge about metabolic capacity is important in drug therapy].PMID 1738265Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Semantic proximity Read ↗

[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].Semantic proximity Read ↗

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].Semantic proximity Read ↗

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.Semantic proximity Read ↗

[Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.Semantic proximity Read ↗

pNAT and CYP2D6 gene polymorphism in epileptic patients.Semantic proximity Read ↗

[Assessment of biotransformation capacity following oral administration of various model substances as cocktail].Semantic proximity Read ↗

Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.